EP3137107A4 - Immunkombinationstherapie und radiotherapie zur behandlung von her-2-positiven karzinomen - Google Patents

Immunkombinationstherapie und radiotherapie zur behandlung von her-2-positiven karzinomen Download PDF

Info

Publication number
EP3137107A4
EP3137107A4 EP15786740.9A EP15786740A EP3137107A4 EP 3137107 A4 EP3137107 A4 EP 3137107A4 EP 15786740 A EP15786740 A EP 15786740A EP 3137107 A4 EP3137107 A4 EP 3137107A4
Authority
EP
European Patent Office
Prior art keywords
radiotherapy
treatment
positive cancers
immuno therapy
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15786740.9A
Other languages
English (en)
French (fr)
Other versions
EP3137107A1 (de
Inventor
Yvonne Paterson
Nicola Mason
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/268,436 external-priority patent/US20140234370A1/en
Priority claimed from PCT/US2015/017559 external-priority patent/WO2015130810A2/en
Priority claimed from US14/669,629 external-priority patent/US10016617B2/en
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of EP3137107A1 publication Critical patent/EP3137107A1/de
Publication of EP3137107A4 publication Critical patent/EP3137107A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP15786740.9A 2014-05-02 2015-04-02 Immunkombinationstherapie und radiotherapie zur behandlung von her-2-positiven karzinomen Withdrawn EP3137107A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14/268,436 US20140234370A1 (en) 2009-11-11 2014-05-02 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US201462076411P 2014-11-06 2014-11-06
PCT/US2015/017559 WO2015130810A2 (en) 2014-02-25 2015-02-25 Compositions and methods for the treatment of her2/neu over-expressing tumors
US14/669,629 US10016617B2 (en) 2009-11-11 2015-03-26 Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
PCT/US2015/024048 WO2015167748A1 (en) 2014-05-02 2015-04-02 Combination immuno therapy and radiotherapy for the treatment of her-2-positive cancers

Publications (2)

Publication Number Publication Date
EP3137107A1 EP3137107A1 (de) 2017-03-08
EP3137107A4 true EP3137107A4 (de) 2018-01-17

Family

ID=54359144

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15786740.9A Withdrawn EP3137107A4 (de) 2014-05-02 2015-04-02 Immunkombinationstherapie und radiotherapie zur behandlung von her-2-positiven karzinomen

Country Status (11)

Country Link
EP (1) EP3137107A4 (de)
JP (1) JP2017514904A (de)
KR (1) KR20170002552A (de)
CN (1) CN106794234A (de)
AU (1) AU2015253737A1 (de)
CA (1) CA2947677A1 (de)
IL (1) IL248704A0 (de)
MA (1) MA39942A (de)
MX (1) MX2016014367A (de)
SG (1) SG11201609135VA (de)
WO (1) WO2015167748A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
AU2013232291B8 (en) 2012-03-12 2016-07-21 Advaxis, Inc. Suppressor cell function inhibition following listeria vaccine treatment
KR20160130774A (ko) 2014-02-18 2016-11-14 어드박시스, 인크. 바이오마커 지도된 다중-표적 면역치료
WO2015164121A1 (en) 2014-04-24 2015-10-29 Advaxis, Inc. Recombinant listeria vaccine strains and methods of producing the same
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
EP3464560A4 (de) * 2016-06-03 2020-01-15 Etubics Corporation Zusammensetzungen und verfahren für tumorimpfung und immuntherapie mit her2/neu
AU2017367642A1 (en) 2016-11-30 2019-05-30 Advaxis, Inc. Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
AU2018336988B2 (en) 2017-09-19 2023-06-22 Advaxis, Inc. Compositions and methods for lyophilization of bacteria or Listeria strains

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050281783A1 (en) * 2003-10-15 2005-12-22 Kinch Michael S Listeria-based EphA2 vaccines
WO2011100754A1 (en) * 2010-02-15 2011-08-18 The Trustees Of The University Of Pennsylvania Live listeria-based vaccines for central nervous system therapy
WO2011149852A1 (en) * 2010-05-23 2011-12-01 Aduro Biotech Methods and compositions using listeria for adjuvant treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US6855320B2 (en) 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
US7432304B2 (en) * 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
US9084747B2 (en) * 2009-11-11 2015-07-21 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of HER2/NEU over-expressing tumors
US9017660B2 (en) * 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050281783A1 (en) * 2003-10-15 2005-12-22 Kinch Michael S Listeria-based EphA2 vaccines
WO2011100754A1 (en) * 2010-02-15 2011-08-18 The Trustees Of The University Of Pennsylvania Live listeria-based vaccines for central nervous system therapy
WO2011149852A1 (en) * 2010-05-23 2011-12-01 Aduro Biotech Methods and compositions using listeria for adjuvant treatment of cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CRISTER CEBERG ET AL.: "Co-operative radio-immune-stimulating cancer therapy", TRENDS IN CANCER RESEARCG, 2013, pages 87 - 108, XP002776527, Retrieved from the Internet <URL:https://www.researchgate.net/profile/Bertil_Persson/publication/260291271_Co-operative_Radio-Immune-Stimulating_Cancer_Therapy/links/0a85e530ccf9777133000000.pdf> [retrieved on 20171208] *
HANNAN RAQUIBUL ET AL: "Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer", CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 61, no. 12, December 2012 (2012-12-01), pages 2227 - 2238, XP002776528 *
See also references of WO2015167748A1 *

Also Published As

Publication number Publication date
JP2017514904A (ja) 2017-06-08
MA39942A (fr) 2017-03-08
AU2015253737A1 (en) 2016-12-22
CN106794234A (zh) 2017-05-31
MX2016014367A (es) 2017-06-30
CA2947677A1 (en) 2015-11-05
KR20170002552A (ko) 2017-01-06
SG11201609135VA (en) 2016-11-29
IL248704A0 (en) 2017-01-31
EP3137107A1 (de) 2017-03-08
WO2015167748A1 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
IL291844B1 (en) smc combined therapy for cancer treatment
IL290149A (en) Combined treatment for cancer
GB201719076D0 (en) Particles for the treatment of cancer in combination with radiotherapy
HK1247129A1 (zh) 治療癌症的聯合療法
EP3672604A4 (de) Kombinationsimmuntherapie und cytokinkontrolltherapie zur krebsbehandlung
HK1251475A1 (zh) 用於癌症治療的聯合療法
EP3206987A4 (de) Nanopartikel zur fotodynamischen therapie, röntgeninduzierte fotodynamische therapie, radiotherapie, chemotherapie, immuntherapie und kombinationen davon
IL267795A (en) Combined treatment for cancer
EP3166640A4 (de) Kombinationstherapiezusammensetzung und verfahren zur behandlung von krebs
EP3258943A4 (de) Kombinationsimmuntherapie und cytokin-kontrolltherapie zur behandlung von krebs
IL248704A0 (en) Combined treatment with immunotherapy and radiotherapy for the treatment of cancers that express her-2
EP3407978A4 (de) Kombinationstherapie zur behandlung von krebs
EP3678663A4 (de) Kombinationstherapie zur behandlung von krebs
EP3258965A4 (de) Kombinationstherapie für krebsbehandlung
EP3226901A4 (de) Kombinationstherapie zur behandlung von krebs
EP3185884A4 (de) Kombinationstherapie zur krebsbehandlung
EP3706746A4 (de) Kombinationstherapie mit apatinib zur behandlung von krebs
IL281845A (en) Combined treatment for cancer
IL264589A (en) Combined treatment for pancreatic cancer
IL284162A (en) Integrated healing for cancer treatment
IL266993A (en) Combined therapy for cancer treatment
IL258494A (en) Rational combined therapy for cancer treatment
IL263905A (en) Combined cancer treatment
IL253642A0 (en) Combined treatment for cancer
EP3706752A4 (de) Kombinationstherapie für krebsbehandlung

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20161201

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

A4 Supplementary search report drawn up and despatched

Effective date: 20171220

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/00 20060101ALI20171211BHEP

Ipc: C12N 1/20 20060101ALI20171211BHEP

Ipc: C12N 1/12 20060101AFI20171211BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1232771

Country of ref document: HK

17Q First examination report despatched

Effective date: 20190104

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20190913

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20200124

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1232771

Country of ref document: HK